US5854239A
(en)
*
|
1993-12-29 |
1998-12-29 |
Pfizer Inc. |
Diazabicyclic neuokinin antagonists
|
FR2786770B1
(fr)
*
|
1998-12-04 |
2001-01-19 |
Synthelabo |
Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
|
WO2001095904A1
(en)
*
|
2000-06-12 |
2001-12-20 |
University Of Rochester |
Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
|
FR2812635B1
(fr)
*
|
2000-08-01 |
2002-10-11 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
|
SE0003795D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Pharmaceutically useful compounds
|
FR2825705B1
(fr)
*
|
2001-06-08 |
2005-05-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
|
FR2835186B1
(fr)
*
|
2002-01-28 |
2006-10-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
|
FR2844273B1
(fr)
|
2002-09-05 |
2008-04-04 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
|
US7439253B2
(en)
|
2002-12-06 |
2008-10-21 |
Novexel |
Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
|
FR2848210B1
(fr)
*
|
2002-12-06 |
2007-10-19 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
|
KR101412339B1
(ko)
|
2004-07-15 |
2014-06-25 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
WO2006135783A2
(en)
*
|
2005-06-10 |
2006-12-21 |
Wisconsin Alumni Research Foundation |
Compositions and methods for modulating angiogenesis
|
NZ565111A
(en)
|
2005-07-15 |
2011-10-28 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
TWI454262B
(zh)
*
|
2006-11-02 |
2014-10-01 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
WO2008084261A1
(en)
|
2007-01-10 |
2008-07-17 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
RS53862B1
(en)
|
2008-01-18 |
2015-08-31 |
Merck Sharp & Dohme Corp. |
INHIBITOR BETA-LACTAMASE
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132487A1
(en)
|
2009-05-12 |
2010-11-18 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
CN102595902B
(zh)
|
2009-05-12 |
2015-04-29 |
阿尔巴尼分子研究公司 |
7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
|
ES2446971T3
(es)
|
2009-05-12 |
2014-03-11 |
Albany Molecular Research, Inc. |
Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
|
FR2951171A1
(fr)
*
|
2009-10-09 |
2011-04-15 |
Novexel |
Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
|
NZ599343A
(en)
|
2009-10-14 |
2014-05-30 |
Merck Sharp & Dohme |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2624045C2
(ru)
|
2010-08-17 |
2017-06-30 |
Сирна Терапьютикс,Инк |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
CA2822758C
(en)
*
|
2010-12-22 |
2018-03-20 |
Meiji Seika Pharma Co., Ltd. |
Optically active diazabicyclooctane derivative and process for preparing the same
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
MX348974B
(es)
*
|
2011-08-27 |
2017-07-04 |
Wockhardt Ltd |
Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
|
RU2570423C2
(ru)
*
|
2011-08-30 |
2015-12-10 |
Вокхардт Лимитед |
Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
|
BR112014003476A2
(pt)
*
|
2011-09-13 |
2017-03-01 |
Wockhardt Ltd |
compostos contendo nitrogênio e seu uso
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
AR090539A1
(es)
*
|
2012-04-02 |
2014-11-19 |
Astrazeneca Ab |
COMPUESTOS INHIBIDORES DE b LACTAMASA
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
BR112014029368B1
(pt)
*
|
2012-05-30 |
2020-10-27 |
Meiji Seika Pharma Co., Ltd |
inibidor de beta-lactamase e processo para preparar o mesmo
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP3610890A1
(en)
|
2012-11-14 |
2020-02-19 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
PT2925888T
(pt)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Composições e métodos para tratamento do cancro
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JP6285969B2
(ja)
*
|
2013-03-08 |
2018-02-28 |
ウォックハート リミテッド |
(2s,5r)−7−オキソ−6−スルホオキシ−2−[((3r)−ピペリジン−3−カルボニル)−ヒドラジノカルボニル]−1,6−ジアザ−ビシクロ[3.2.1]オクタンの調製のためのプロセス
|
RU2627698C2
(ru)
*
|
2013-03-08 |
2017-08-10 |
Вокхардт Лимитед |
Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение
|
AU2013380575B2
(en)
*
|
2013-03-08 |
2016-07-07 |
Wockhardt Limited |
A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
|
RU2621051C2
(ru)
*
|
2013-03-08 |
2017-05-31 |
Вокхардт Лимитед |
Способ получения (2s, 5r)-моно-{ [(4-аминопиперидин-4-ил)карбонил]-7-оксо-1, 6-диазабицикло[3.2.1]окт-6-ил} ового сложного эфира серной кислоты
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
MY176278A
(en)
*
|
2013-09-24 |
2020-07-27 |
Meiji Seika Pharma Co Ltd |
Process for producing diazabicyclooctane derivative and intermediate thereof
|
HUE044061T2
(hu)
|
2014-11-17 |
2019-09-30 |
Entasis Therapeutics Ltd |
Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
|
MX2017012545A
(es)
|
2015-04-03 |
2018-09-28 |
Mutabilis |
Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
|
PL3512851T3
(pl)
|
2016-09-16 |
2022-11-14 |
Entasis Therapeutics Limited |
Związki stanowiące inhibitory beta-laktamazy
|
EA038393B1
(ru)
|
2017-05-08 |
2021-08-20 |
Энтасис Терапеутикс, Инк. |
Соединения и способы для лечения бактериальных инфекций
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
CN108610313B
(zh)
*
|
2018-06-08 |
2022-03-04 |
三峡大学 |
一种酶抑制剂及其应用
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|